🔎 Trials Near Me

Beranda › Limfoma › Ohio

Uji klinis Limfoma di Ohio

29 studi untuk Limfoma mencari peserta di lokasi di Ohio.

Kota di Ohio

Teks studi resmi (Bahasa Inggris)

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • University Hospitals Seidman Cancer Center, Cleveland
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06343311

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

  • University Hospitals Cleveland Medical Center, Cleveland
Menerima pesertaFase 2
1 Month – 17 Years · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT04570423

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • University Hospitals Cleveland Medical Center, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07192471

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

  • Cleveland Clinic, Cleveland
  • The Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07015242

Epco, Zanu, Ritux for R/R FL or MZL

  • The Ohio State University Wexner Medical Center, Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06563596

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaFase 1
24 Months – 18 Years · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06441331

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  • Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT04301076

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • University of Cincinnati, Cincinnati
  • The Cleveland Clinic Foundation, Cleveland
  • The Ohio State University, Columbus
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07221500

Collection of Tissue Samples for Cancer Research

  • Ohio State University, Columbus
Menerima pesertaStudi observasional
2 Months · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT00900198

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaFase 1/2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT04870944

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  • Research Site, Cleveland
Menerima pesertaFase 3
Usia 18 hingga 18 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07509151

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
  • Cleveland Clinic, Cleveland
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

  • Cleveland Clinic, Cleveland
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06678659

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Cincinnatti Medical Center, Cincinnatti
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06528301

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • The Ohio State University Wexner Medical Center, Columbus
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Oncology Hematology Care Clinical Trials, Cincinnati
  • University of Cincinnati, Cincinnati
  • Cleveland Clinical Taussig Cancer Center, Cleveland
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • The Ohio State University Wexner Medical Center James Cancer, Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

  • University Hospitals Cleveland Medical Center, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jul 2026 · NCT07465835

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Cincinnati Medical Center, Cincinnati
  • Cleveland Clinic, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Columbus
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT05475925

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT01790152

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

  • The Ohio State University, Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT06801002

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Cleveland Clinic, Cleveland
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Apr 2026 · NCT03328078

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT07356245

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Gabrail Cancer Center Research,, Canton
Menerima pesertaFase 1/2
Usia 12 hingga 95 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04329728

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Cleveland Clinic, Cleveland
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Nov 2025 · NCT06916767

HPC Offered for PRESERVE Expansion

  • The Ohio State University Medical Center, Columbus
Menerima pesertaStudi observasional
Usia 12 hingga 80 · Semua jenis kelamin · Diperbarui 28 Agu 2025 · NCT07145411

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.